Clinical Trials Logo

Recurrent Head and Neck Cancer clinical trials

View clinical trials related to Recurrent Head and Neck Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04260126 Active, not recruiting - Clinical trials for HPV Positive Oropharyngeal Squamous Cell Carcinoma

Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC

VERSATILE002
Start date: March 29, 2021
Phase: Phase 2
Study type: Interventional

VERSATILE-002 is a Phase 2, open-label, multicenter study of the efficacy and safety of PDS0101 administered in combination with pembrolizumab in adults with HPV16 and PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

NCT ID: NCT03691714 Active, not recruiting - Clinical trials for Head and Neck Cancer

Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Start date: October 23, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to test the combination of the anti-cancer drugs durvalumab, the study drug, and cetuximab as a treatment for metastatic or recurrent head and neck cancer. Participants will receive both durvalumab and cetuximab.

NCT ID: NCT02289209 Active, not recruiting - Clinical trials for Carcinoma, Squamous Cell of Head and Neck

Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck

Start date: January 10, 2019
Phase: Phase 2
Study type: Interventional

Eligible participants with locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck will be treated with reirradiation combined with anti-PD-1 mAb MK-3475 (generic name: pembrolizumab, trade name Keytruda®).